These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 23333526)
21. New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Gaïni S; Pedersen SS; Koldkaer OG; Pedersen C; Moestrup SK; Møller HJ Clin Exp Immunol; 2008 Mar; 151(3):423-31. PubMed ID: 18190604 [TBL] [Abstract][Full Text] [Related]
22. Clinical significance of variceal hemorrhage in recent years in patients with liver cirrhosis and esophageal varices. Park DK; Um SH; Lee JW; Lee JB; Kim YS; Park CH; Jin YT; Chun HJ; Lee HS; Lee SW; Choi JH; Kim CD; Ryu HS; Hyun JH J Gastroenterol Hepatol; 2004 Sep; 19(9):1042-51. PubMed ID: 15304123 [TBL] [Abstract][Full Text] [Related]
23. High-D-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Primignani M; Dell'Era A; Bucciarelli P; Bottasso B; Bajetta MT; de Franchis R; Cattaneo M Dig Liver Dis; 2008 Nov; 40(11):874-81. PubMed ID: 18329968 [TBL] [Abstract][Full Text] [Related]
24. [The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis]. Zhang JY; Kuai JH; Jia JD; Wang BE; Qin CY Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):263-5. PubMed ID: 19403023 [TBL] [Abstract][Full Text] [Related]
25. Role of hepatic hemodynamic study in the evaluation of patients with cirrhosis. Dittrich S; de Mattos AA; Becker M; Gonçaves DM; Cheinquer H Hepatogastroenterology; 2003; 50(54):2052-6. PubMed ID: 14700005 [TBL] [Abstract][Full Text] [Related]
36. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Merkel C; Zoli M; Siringo S; van Buuren H; Magalotti D; Angeli P; Sacerdoti D; Bolondi L; Gatta A Am J Gastroenterol; 2000 Oct; 95(10):2915-20. PubMed ID: 11051368 [TBL] [Abstract][Full Text] [Related]
37. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Escorsell A; Bordas JM; Castañeda B; Llach J; García-Pagán JC; Rodés J; Bosch J Hepatology; 2000 May; 31(5):1061-7. PubMed ID: 10796880 [TBL] [Abstract][Full Text] [Related]
38. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725 [TBL] [Abstract][Full Text] [Related]
39. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375 [TBL] [Abstract][Full Text] [Related]
40. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]